Today’s Market Runner: BioTime, Inc. Can’t Burn Your Long Portfolio. Has Another Strong Session

Today's Market Runner: BioTime, Inc. Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! About 223,120 shares traded hands. BioTime, Inc. (NYSEMKT:BTX) has declined 8.25% since April 4, 2016 and is downtrending. It has underperformed by 9.34% the S&P500.
The move comes after 8 months positive chart setup for the $332.92M company. It was reported on Nov, 4 by Barchart.com. We have $8.34 PT which if reached, will make NYSEMKT:BTX worth $529.34 million more.

Analysts await BioTime, Inc. (NYSEMKT:BTX) to report earnings on November, 14. They expect $-0.19 EPS, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.11 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 72.73% negative EPS growth.

According to Zacks Investment Research, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.”

Insitutional Activity: The institutional sentiment increased to 2.25 in 2016 Q2. Its up 1.29, from 0.96 in 2016Q1. The ratio improved, as 3 funds sold all BioTime, Inc. shares owned while 13 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 38.13 million shares or 10.80% more from 34.42 million shares in 2016Q1.
Fifth Third Fincl Bank, a Ohio-based fund reported 4,200 shares. Family Management Corp holds 0.14% of its portfolio in BioTime, Inc. (NYSEMKT:BTX) for 93,500 shares. Raymond James Financial Incorporated last reported 0% of its portfolio in the stock. Carroll Fin Associates has invested 0.01% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Legal General Grp Inc Public Ltd Liability holds 11,810 shares or 0% of its portfolio. Citigroup has 0% invested in the company for 8,502 shares. Moreover, Teachers has 0% invested in BioTime, Inc. (NYSEMKT:BTX) for 92,984 shares. Blackrock last reported 4,231 shares in the company. Ladenburg Thalmann Financial Service holds 0% or 825 shares in its portfolio. Blackrock Fund Advisors has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Blackrock Institutional Trust Na has 1.93 million shares for 0% of their US portfolio. Credit Suisse Ag holds 0% or 42,890 shares in its portfolio. The United Kingdom-based Barclays Public has invested 0% in BioTime, Inc. (NYSEMKT:BTX). Moreover, Principal Gp Inc has 0% invested in BioTime, Inc. (NYSEMKT:BTX) for 11,249 shares. Spot Trading Ltd Company accumulated 24,788 shares or 0% of the stock.

More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: Businesswire.com which released: “BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress” on November 03, 2016, also Reuters.com with their article: “BRIEF-Biotime Inc. says qtrly earnings per share $0.30” published on November 03, 2016, Businesswire.com published: “Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring …” on January 12, 2016. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: Businesswire.com and their article: “BioTime, Inc. to Announce Third Quarter Results on November 3, 2016” published on October 24, 2016 as well as Businesswire.com‘s news article titled: “BioTime, Inc. to Report Second Quarter Results on August 9, 2016” with publication date: July 27, 2016.

BTX Company Profile

BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment